13 Sept 2024 • Indian Immunologicals Limited (IIL), a vaccine manufacturer, and the Indian Council of Medical Research (ICMR) have signed a Memorandum of Association (MoA) for the clinical development of a Zika vaccine.

Under the agreement, the ICMR will bear the costs associated with the Phase I clinical trials, including expenses for conducting, investigating and monitoring the trials. These trials will be carried out at ICMR’s network sites across India.

India has reported Zika cases in several states. According to the Ministry of Health, as of July 22, 2024, there have been 537 registered Zika cases in the country.

Currently, no vaccine is available for Zika prevention. IIL, in collaboration with Griffith University in Australia, has developed the codon de-optimized live attenuated Zika vaccine.

Source: CNBCTV | Read full story